Search Results
Dec 02, 2025, 06:00 ET TETRA TECHNOLOGIES, INC. AND MAGRATHEA METALS, INC. ADVANCE JOINT VENTURE PLANS TO PRODUCE MAGNESIUM IN ARKANSAS
expertise and a world-class magnesium resource base from our Southwest Arkansas brine acreage. Magrathea has already secured Defense Production Act Title III funding from the Department of War to support its Commercial Phase 1, planned to be on-site at TETRA's Evergreen Plant. We are optimistic that further
More news about: TETRA Technologies, Inc.
Dec 02, 2025, 06:00 ET Hyperscale Data Bitcoin Treasury at Approximately $72.25 Million
treasury strategy is a powerful validation of Hyperscale Data's disciplined approach to its accumulation of Bitcoin," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "We believe that Bitcoin is a foundational asset for the future of the Company and remain committed
More news about: Hyperscale Data Inc.
Dec 02, 2025, 03:20 ET Brightstar Lottery PLC Announces a Benchmark Offering of Senior Secured Notes Due 2033
Order")), (ii) falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Financial Promotion Order, (iii) who are outside the United Kingdom, or (iv) to whom an invitation or inducement to engage in investment activity within the meaning of Section 21 of
More news about: Brightstar Lottery PLC
Dec 02, 2025, 02:00 ET Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
public.About OSVYRTI and JUBEREQThe approval of OSVYRTI and JUBEREQ was based on results from two trials: a Phase I trial and a Phase III trial that met their primary endpoints. The Phase I trial was a randomized, double-blind, three-arm pharmacokinetic (PK) study comparing JUBEREQ to Xgeva
More news about: Accord Healthcare
Dec 02, 2025, 02:00 ET Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
public.About OSVYRTI and JUBEREQThe approval of OSVYRTI and JUBEREQ was based on results from two trials: a Phase I trial and a Phase III trial that met their primary endpoints. The Phase I trial was a randomized, double-blind, three-arm pharmacokinetic (PK) study comparing JUBEREQ to Xgeva
More news about: Accord Healthcare
Dec 01, 2025, 19:35 ET Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
potential as a disease-modifying therapy for AD.Currently, etalanetug is being evaluated in two ongoing clinical studies: the Tau NexGen Phase II/III trial in DIAD, conducted under the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) and led by Washington University School of Medicine in
More news about: Eisai Inc.
Dec 01, 2025, 17:00 ET Highland Opportunities and Income Fund Announces the Regular Monthly Distribution
collateralized loan obligations and asset-backed securities), convertible and preferred securities, equities (public and private), and futures and options; and (iii) floating rate loans and other securities deemed to be floating rate investments.The Fund declares and pays distributions monthly.About
More news about: Highland Opportunities and Income Fund
Dec 01, 2025, 16:24 ET JOHN HANCOCK CLOSED-END FUNDS DECLARE MONTHLY DISTRIBUTIONS
HPSPreferred Income Fund III$0.1100
More news about: John Hancock Investment Management
Dec 01, 2025, 16:15 ET ONE Gas Issues 2026 Financial Guidance
prior to or when they become due and to fund our operations and capital expenditures, either through (i) cash on hand, (ii) operating cash flow, or (iii) access to the capital markets and other sources of liquidity;our ability to obtain capital on commercially reasonable terms, or on terms acceptable
More news about: ONE Gas, Inc.
Dec 01, 2025, 16:05 ET Calamos Investments Closed-End Funds (NASDAQ: CHI, CHY, CSQ, CGO, CHW, CCD and CPZ) Announce Monthly Distributions and Required Notifications of Sources of Distribution
distribution amount per common share, attributable to (i) current and prior fiscal year net investment income, (ii) net realized short-term capital gain, (iii) net realized longterm capital gain and (iv) return of capital or other capital source as a percentage of the total distribution amount. These percentages
More news about: Calamos Investments
Dec 01, 2025, 15:43 ET FLY Investors are Encouraged to Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the Securities Class Action Against Firefly Aerospace Inc.
its Spacecraft Solutions offerings; (ii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; and (iii) the foregoing, once revealed, would likely have a material negative impact on the Company.Plaintiff alleges that on September 22,
More news about: Robbins LLP
Dec 01, 2025, 15:34 ET Triple Triumph: Three Members of One Family Graduate Together
where Carver has worked since 2015, BMW, where Carver III is employed in maintenance, and GE, where Carletta is a CNC machinist.Commencement is a crossroads of completion and new beginnings, especially for the Blassingame family. Carver III is following his Dad's path into the bachelor's degree
More news about: Greenville Technical College
Dec 01, 2025, 15:30 ET Grid Upgrades Aim to Reduce Outages, Speed Power Restoration for Westmoreland County Customers
Larger PlanThe upgrades are part of FE PA's Long Term Infrastructure Improvement Plan (LTIIP) III, which fast-tracks important investments in electric system reliability. The LTIIP III investment for the West Penn district's service area is $368 million.LTIIP is part of Energize365,
More news about: FirstEnergy Corp.
Dec 01, 2025, 12:00 ET Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
More news about: Citius Oncology, Inc.
Dec 01, 2025, 11:25 ET APPLE PAY TO ATMS, FASHION TO FITNESS, AND GIFT IDEAS FOR EVERYONE, (RED) SOLVES HOLIDAY SHOPPING FOR THE SEASON
The (RED) Holiday Edit Vol. III, is generously supported by Merck (known as MSD outside the U.S. and Canada), and continues through the holiday season. From Bank of America's ATM network
More news about: (RED)
Dec 01, 2025, 10:46 ET Generate:Biomedicines rozpoczyna globalne badania III fazy nad GB-0895, przeciwciałem o długim działaniu skierowanym przeciwko limfopoetynie zrębu grasicy (TSLP) przeznaczonym do leczenia astmy ciężkiej, opracowanym przy użyciu sztucznej inteligencji
których choroba nie jest wystarczająco kontrolowana przy pomocy obecnie stosowanych terapii.Są to pierwsze globalne badania III fazy dotyczące przeciwciała o długim działaniu skierowanego przeciwko TSLP o kluczowym znaczeniu, ponieważ GB-0895 stanowi kolejny krok naprzód w dziedzinie
More news about: Generate:Biomedicines
Dec 01, 2025, 10:00 ET Saxena White P.A. and Equity Litigation Group LLP Announce a Proposed Settlement for All Record and Beneficial Owners of Shares of the Keypath Education International, Inc., Common Stock, Including Holders of CHESS Depository Interests
Plaintiffs should be finally appointed as Class Representatives for the Class and Plaintiffs' Counsel should be finally appointed as Counsel for the Class; (iii) determine whether the proposed Settlement should be approved as fair, reasonable, and adequate to Plaintiffs and the other members of the Class and
More news about: Saxena White P.A.
Dec 01, 2025, 09:48 ET Caterpillar Raises $15.2 Million for United Way, Named a 2025 Leading Corporate Partner
industries we serve; (ii) commodity price changes, material price increases, fluctuations in demand for our products or significant shortages of material; (iii) government monetary or fiscal policies; (iv) political and economic risks, commercial instability and events beyond our control in the countries in
More news about: Caterpillar Inc.
Dec 01, 2025, 09:00 ET Stride, Inc. (LRN) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
enrollment numbers by retaining "ghost students"; (ii) cutting staffing costs by assigning teachers' caseloads far beyond the required statutory limits; (iii) ignoring compliance requirements, including background checks and licensure laws for its employees, and ignoring federally mandated special education
More news about: Robbins Geller Rudman & Dowd LLP
Dec 01, 2025, 09:00 ET Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911
progressing, with first patient dosing completed in July 2025 and an interim analysis planned after data from at least 120 patients are collected. A Phase III trial is expected to begin by the end of 2026 based on the Phase II outcomes. The Phase IIa trial application has recently been accepted by the U.S.
More news about: Mabwell
Dec 01, 2025, 09:00 ET Circular Genomics Announces Closure of $15 Million Series A Financing to Advance First-in-Class Circular RNA Platform for Early Detection of Alzheimer's Disease
rare opportunity to invest in a truly transformative diagnostic platform that addresses one of healthcare's most pressing unmet needs," said Joe Cook III, Managing Director at Mountain Group Partners. "The company's circular RNA technology provides a fundamentally different and more comprehensive view
More news about: Circular Genomics
Dec 01, 2025, 08:45 ET Skye Bioscience, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SKYE
effective than defendants had led investors to believe; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.DEADLINE: January 16, 2026 Shareholders
More news about: The Gross Law Firm
Dec 01, 2025, 08:45 ET DexCom, Inc. Class Action: The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 - DXCM
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: The Gross Law Firm
Dec 01, 2025, 08:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 12, 2026 in Firefly Aerospace Inc. Lawsuit - FLY
for its Spacecraft Solutions offerings; (ii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (iii) the foregoing, once revealed, would likely have a material negative impact on the Company; and (iv) as a result, the offering documents and defendants'
More news about: The Gross Law Firm
Dec 01, 2025, 08:30 ET YY Group Secures 3-Year Facility Maintenance Contract with a Major International Bank
forward-looking statement. These factors include, but are not limited to, (i) growth of the hospitality market, (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, and (vi) our future business
More news about: YY Group Holding Limited